Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.1K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

631
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and Structural Characterization of Viroporins from Deadly Hemorrhagic Viruses.

Viruses·2025
Same author

A bacteria-based search for drugs against avian and swine flu yields a potent and resistance-resilient channel blocker.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Sensing Microorganisms Using Rapid Detection Methods: Supramolecular Approaches.

Biosensors·2025
Same author

Supramolecular Adhesives Inspired by Nature: Concept and Applications.

Biomimetics (Basel, Switzerland)·2025
Same author

Hydrogen Bond Strengthens Acceptor Group: The Curious Case of the C-H···O=C Bond.

International journal of molecular sciences·2024
Same author

Viroporins of Mpox Virus.

International journal of molecular sciences·2023

Related Experiment Video

Updated: Jan 15, 2026

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

14.8K

Ion-Channel-Targeting Drugs for Chikungunya Virus.

Hiya Lahiri1,2, Kingshuk Basu1,2, Isaiah T Arkin1,2

  • 1Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Jerusalem 9190400, Israel.

Molecules (Basel, Switzerland)
|October 16, 2025
PubMed
Summary
This summary is machine-generated.

Researchers screened drugs to block the Chikungunya virus (CHIKV) 6K protein, a key ion channel. This study identifies potential antiviral drug candidates to combat CHIKV infection, offering a new therapeutic strategy.

Keywords:
6K viroporinantiviral drugschikungunya virusion channel blockers

More Related Videos

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

4.2K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.3K

Related Experiment Videos

Last Updated: Jan 15, 2026

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

14.8K
High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

4.2K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.3K

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • Alphaviruses, including Chikungunya virus (CHIKV), cause significant global epidemics.
  • CHIKV infection leads to chikungunya fever (CHIKF), characterized by joint pain and myalgia.
  • Current CHIKV treatment lacks antiviral drugs, despite a recently introduced vaccine.

Purpose of the Study:

  • To identify potential drug candidates that inhibit the CHIKV 6K protein.
  • To explore the 6K protein as a therapeutic target for CHIKV infection.
  • To investigate drug specificity against alphavirus 6K proteins.

Main Methods:

  • Screening of a repurposed drug library.
  • Utilizing three bacteria-based channel assays to detect 6K viroporin blockers.
  • Employing modeling studies to explain observed structural specificities.

Main Results:

  • Several drug compounds were identified as blockers of the CHIKV 6K protein.
  • Some identified blockers also inhibited the 6K protein of Eastern equine encephalitis virus (EEEV).
  • Drug efficacy demonstrated structural specificity, suggesting targeted inhibition.

Conclusions:

  • The study provides a foundational set of compounds for developing novel CHIKV inhibitors.
  • Targeting the 6K viroporin presents a promising antiviral strategy.
  • Further research into drug specificity can refine therapeutic development against alphaviruses.